Navigation Links
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
Date:5/6/2008

Milestone Payments slated for reduction from $25 Million to $7 Million,

Royalties from 10-12% to 4%

HOPKINTON, Mass., May 6 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced an agreement with BioAxone Therapeutic, Inc., of Montreal, Canada, whereby, upon payment by Alseres of an option fee of $7 million on or before October 27, 2008, Alseres may exercise an option to amend the Company's Cethrin License Agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Pursuant to the option agreement, the pre-commercial milestone payments in the amended license agreement will be reduced from $25 million to $7 million payable on or before December 31, 2009. In addition, the sales-based royalties in the amended license agreement will be reduced from 10-12% to 4% for spinal cord injury and 1% for all other indications. Finally, the amended license agreement will eliminate all development milestones related to Cethrin.

"This agreement represents a major step forward for Alseres in realizing the full value of our Cethrin spinal cord program and our Rho inhibitor technology platform," stated Peter Savas, Chairman and Chief Executive Officer. "Our strategy for our spinal cord injury program and our other regenerative therapeutics is to demonstrate efficacy in humans and then seek attractive partnerships for the assets. In addition to reducing the future cash burdens of the license, we believe that the reduction in our future royalty obligations will allow us to more freely explore worldwide collaboration and partnership opportunities not only in spinal cord injury b
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... , , NEW YORK, Sept. 16 ... Trustees, today announced the appointment of Alan Kadish, M.D., as senior ... , PHOTO: http://www.flickr.com/photos/tourocollege/3923514965/ ... institution in the United States. The college was founded by ...
... , SEBASTOPOL, Calif., Sept. 16 As ... yerba mate is quickly catching on as the newest organic ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090916/NE76510 ) , , ... the yerba mate beverage category, is driving yerba mate into the mainstream ...
... YONKERS, N.Y., Sept. 16 Welcome to ... Consumer Reports and ConsumerReportsHealth.org cover issues pertaining ... (including natural medicines), mental health, diet and nutrition, food safety, ... products, rates the effectiveness and affordability of prescription drugs, and ...
... HONG KONG, Sept. 16 /PRNewswire-Asia/ -- ... on September 10, reporters were informed that the,First World ... Endoscopy Physicians) and the First World Endoscopy Technology Expo,will ... , Professor Zhang Yangde, the ...
... used to alleviate the shortage of available liver donors. Accurate ... donor and recipient is crucial. Scholars of different countries established ... the most accurate for Chinese adults has remained unclear. ... published on August 28, 2009 in the World Journal ...
... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
Cached Medicine News:Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 3Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 4Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 2Health News:Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 3Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:Consumer Reports Health News 5Health News:Consumer Reports Health News 6Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 2Health News:The First World Conference of Endoscopy Physicians will be Held December 18-20, 2009, in Hong Kong 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: